Epidemiology and vaccine of porcine epidemic diarrhea virus in China: a mini-review

SUN, Dongbo; WANG, Xinyu; WEI, Shan; CHEN, Jianfei; FENG, Li

On the basis of inactivated PEDV cell cultures, Ma et al. prepared an inactivated, bivalent TGEV and PEDV vaccine [26] . Tong et al. prepared an attenuated, bivalent TGEV and PEDV vaccine based on the attenuated PEDV vaccine [37] . The inactivated, bivalent TGEV and PEDV vaccine (1999 to present) and the attenuated, bivalent TGEV and PEDV vaccine (2003) (2004) (2005) (2006) are extensively used in the Chinese pig population, and they play important roles in the control of TGEV and PEDV infections. After the outbreak of PED at the end of 2010, there was a renewed demand for live vaccines that could effectively prevent viral diarrhea diseases of swine. Based on the attenuated, bivalent TGEV and PEDV vaccine, Feng et al. prepared a trivalent TGEV, PEDV and PRoV (G5 type) live vaccine (consisting of an attenuated H strain, an attenuated CV777 strain and the attenuated NX strain), which was licensed on December 31, 2014, by the Chinese Ministry of Agriculture. The results of vaccine clinical trials showed that the immunization protection rate was over 95%, and the incidence of viral diarrheal diseases of swine in experimental farms was reduced from 8-12% to 3-5% [5] . In the future, the TGEV, PEDV and PRoV trivalent live vaccine will serve as an effective tool for the control of viral diarrheal diseases of swine in China, especially PEDV infections.